Single User License
INR 136300
Site License
INR 272600
Corporate User License
INR 408900

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Otitis Media-Pipeline Review, H2 2015

Otitis Media-Pipeline Review, H2 2015


  • Products Id :- GMDHC6882IDB
  • |
  • Pages: 83
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Otitis Media-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Otitis Media-Pipeline Review, H2 2015', provides an overview of the Otitis Media's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Otitis Media

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Otitis Media

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Otitis Media Overview 8

Therapeutics Development 9

Pipeline Products for Otitis Media-Overview 9

Pipeline Products for Otitis Media-Comparative Analysis 10

Otitis Media-Therapeutics under Development by Companies 11

Otitis Media-Therapeutics under Investigation by Universities/Institutes 12

Otitis Media-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Otitis Media-Products under Development by Companies 16

Otitis Media-Products under Investigation by Universities/Institutes 17

Otitis Media-Companies Involved in Therapeutics Development 18

Cellceutix Corporation 18

ContraFect Corporation 19

GlaxoSmithKline Plc 20

Laboratorios SALVAT S.A. 21

Merck & Co., Inc. 22

MerLion Pharmaceuticals Pte Ltd 23

Oticpharma Ltd 24

Otonomy, Inc. 25

Yuhan Corporation 26

Otitis Media-Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(fluocinolone acetonide + ciprofloxacin hydrochloride)-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

betahistine hydrochloride-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

brilacidin tetrahydrochloride-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

CF-309-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ciprofloxacin hydrochloride SR-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ciprofloxacin SR-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

finafloxacin-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

GSK-2189242A-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

P-13-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

solithromycin-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

YH-1177-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Otitis Media-Recent Pipeline Updates 56

Otitis Media-Dormant Projects 74

Otitis Media-Dormant Projects 74

Otitis Media-Product Development Milestones 76

Featured News & Press Releases 76

May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes 76

Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application 76

Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference 76

Apr 21, 2015: Otonomy to Present AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference 77

Mar 26, 2015: Otonomy Initiates Phase 2 Clinical Trial for AuriPro in Label Expansion Indication 77

Feb 26, 2015: Otonomy Submits New Drug Application to the FDA for AuriPro 78

Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes 78

Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 79

May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery 79

Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections 80

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

Number of Products under Development for Otitis Media, H2 2015 9

Number of Products under Development for Otitis Media-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Number of Products under Investigation by Universities/Institutes, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 14

Comparative Analysis by Early Stage Development, H2 2015 15

Products under Development by Companies, H2 2015 16

Products under Investigation by Universities/Institutes, H2 2015 17

Otitis Media-Pipeline by Cellceutix Corporation, H2 2015 18

Otitis Media-Pipeline by ContraFect Corporation, H2 2015 19

Otitis Media-Pipeline by GlaxoSmithKline Plc, H2 2015 20

Otitis Media-Pipeline by Laboratorios SALVAT S.A., H2 2015 21

Otitis Media-Pipeline by Merck & Co., Inc., H2 2015 22

Otitis Media-Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2015 23

Otitis Media-Pipeline by Oticpharma Ltd, H2 2015 24

Otitis Media-Pipeline by Otonomy, Inc., H2 2015 25

Otitis Media-Pipeline by Yuhan Corporation, H2 2015 26

Assessment by Monotherapy Products, H2 2015 27

Assessment by Combination Products, H2 2015 28

Number of Products by Stage and Target, H2 2015 30

Number of Products by Stage and Mechanism of Action, H2 2015 32

Number of Products by Stage and Route of Administration, H2 2015 34

Number of Products by Stage and Molecule Type, H2 2015 36

Otitis Media Therapeutics-Recent Pipeline Updates, H2 2015 56

Otitis Media-Dormant Projects, H2 2015 74

Otitis Media-Dormant Projects (Contd..1), H2 2015 75

List of Figures

Number of Products under Development for Otitis Media, H2 2015 9

Number of Products under Development for Otitis Media-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 14

Comparative Analysis by Early Stage Products, H2 2015 15

Assessment by Monotherapy Products, H2 2015 27

Number of Products by Top 10 Targets, H2 2015 29

Number of Products by Stage and Top 10 Targets, H2 2015 29

Number of Products by Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 31

Number of Products by Top 10 Routes of Administration, H2 2015 33

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 33

Number of Products by Top 10 Molecule Types, H2 2015 35

Number of Products by Stage and Top 10 Molecule Types, H2 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Cellceutix Corporation

ContraFect Corporation

GlaxoSmithKline Plc

Laboratorios SALVAT S.A.

Merck & Co., Inc.

MerLion Pharmaceuticals Pte Ltd

Oticpharma Ltd

Otonomy, Inc.

Yuhan Corporation

Otitis Media Therapeutic Products under Development, Key Players in Otitis Media Therapeutics, Otitis Media Pipeline Overview, Otitis Media Pipeline, Otitis Media Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com